Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses: Molecular Therapy
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. - Abstract - Europe PMC
PDF) Modified mRNA Vaccines Protect against Zika Virus Infection
COVID-19 tracker: Regeneron's antibody cocktail hit by safety concerns; Novo's Rybelsus emerging from pandemic slump | FiercePharma
Moderna's coronavirus vaccine shows encouraging early results - The Washington Post
mRNA vaccines - a new era in vaccinology. - Abstract - Europe PMC
Nanomaterials | Free Full-Text | Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives | HTML
Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review)
Moderna's coronavirus vaccine trial is fully enrolled, 37 percent of participants are minorities - The Washington Post
Frontiers | Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections | Immunology
Michael J. Hogan's research works | The Children's Hospital of Philadelphia, PA (CHOP) and other places
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-C
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
Moderna Therapeutics — Wikipédia
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-C
COVID-19 vaccine development and a potential nanomaterial path forward | Nature Nanotechnology
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
mRNA vaccines — a new era in vaccinology | Nature Reviews Drug Discovery
PDF) mRNA vaccines — a new era in vaccinology
Nanotechnology for COVID-19: Therapeutics and Vaccine Research. - Abstract - Europe PMC
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
FDA approves potential COVID-19 vaccine by Moderna for second-stage study - UPI.com
PDF) Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses
mRNA vaccines — a new era in vaccinology | Nature Reviews Drug Discovery
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery - ScienceDirect
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
